CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
工程化 T 细胞和巨噬细胞：攻克实体瘤的两条臂膀
英文原题：Engineered T cells and macrophages: two arms to seize solid tumors.
查看英文原题
Engineered T cells and macrophages: two arms to seize solid tumors.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
CAR-T 细胞治疗多种血液系统恶性肿瘤取得突破后，基于基因修饰免疫细胞的临床试验呈指数增长。然而，利用 CAR 将 T 细胞细胞毒作用重定向至实体瘤仍面临多项障碍，需要增加工程化功能，以改善实体瘤治疗的安全性、迁移能力、疗效和持久性。互补策略尝试利用巨噬细胞的特性，例如吞噬癌细胞、释放细胞因子和呈递抗原，从而诱导更广泛的抗肿瘤免疫应答。在全面概述细胞免疫治疗领域最新技术的基础上，本文提出：工程化设计免疫细胞之间的合成互作，将是推动更安全、更有效活体疗法的下一项突破。
展开英文摘要原文
Following the breakthroughs of CAR T cells in the treatment of several hematological malignancies, clinical trials based on genetically modified immune cells are exponentially increasing. Redirecting T cell cytotoxicity against solid tumors via CARs, however, encountered several barriers that require the engineering of additional functions to improve safety, migration, efficacy, and persistence in solid tumors.
Complementary strategies tried to harness macrophage properties such as cancer cell phagocytosis, cytokine release, and antigen presentation to induce broader antitumorigenic immune response. While providing a comprehensive overview on the latest technologies in the cell-based immunotherapy realm, we propose that engineering synthetic interplay between immune cells will be the next breakthrough to drive safer and more effective living therapeutics.
论文信息
- 作者
- Russo L、De Martino I、Marchetti M、Siciliano V
- 第一作者单位
- Istituto Italiano di Tecnologia - IIT, Largo Barsanti e Matteucci 53, Naples, Italy. Electronic address: luigi.russo2@iit.it.Italy
- 通讯作者单位
- Istituto Italiano di Tecnologia - IIT, Largo Barsanti e Matteucci 53, Naples, Italy. Electronic address: velia.siciliano@iit.it.Italy
- 文献类型
- 综述
- 期刊
- Current opinion in biotechnology2025 Jun
- 原文标识
- PubMed 40147309 · DOI 10.1016/j.copbio.2025.103296